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Abstract
Background: The transcription factor SOX10 is essential for all stages of Schwann cell development including
myelination. SOX10 cooperates with other transcription factors to activate the expression of key myelin genes
in Schwann cells and is therefore a context-dependent, pro-myelination transcription factor. As such, the identification
of genes regulated by SOX10 will provide insight into Schwann cell biology and related diseases. While genome-wide
studies have successfully revealed SOX10 target genes, these efforts mainly focused on myelinating stages of Schwann
cell development. We propose that less-biased approaches will reveal novel functions of SOX10 outside of myelination.
Results: We developed a stringent, computational-based screen for genome-wide identification of SOX10 response
elements. Experimental validation of a pilot set of predicted binding sites in multiple systems revealed that SOX10
directly regulates a previously unreported alternative promoter at SOX6, which encodes a transcription factor that
inhibits glial cell differentiation. We further explored the utility of our computational approach by combining it with
DNase-seq analysis in cultured Schwann cells and previously published SOX10 ChIP-seq data from rat sciatic nerve.
Remarkably, this analysis enriched for genomic segments that map to loci involved in the negative regulation of
gliogenesis including SOX5, SOX6, NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2. Functional studies in Schwann cells
revealed that: (1) all eight loci are expressed prior to myelination and down-regulated subsequent to myelination;
(2) seven of the eight loci harbor validated SOX10 binding sites; and (3) seven of the eight loci are down-regulated
upon repressing SOX10 function.
Conclusions: Our computational strategy revealed a putative novel function for SOX10 in Schwann cells,
which suggests a model where SOX10 activates the expression of genes that inhibit myelination during
non-myelinating stages of Schwann cell development. Importantly, the computational and functional
datasets we present here will be valuable for the study of transcriptional regulation, SOX protein function,
and glial cell biology.
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Background
Schwann cells produce the myelin sheath in the periph-
eral nervous system (PNS), which allows rapid saltatory
conduction and long-range communication between the
central nervous system and innervated muscles and sen-
sory organs. Schwann cell development is directed by a
transcriptional hierarchy that promotes the expression
of proteins important for migration along peripheral
nerves, radial sorting of axons, and the initiation of mye-
lination [1, 2]. Atop this hierarchy sits the transcription
factor SOX10, which is critical for the development and
long-term function of Schwann cells [3] and is expressed
during all stages of Schwann cell development [3, 4].
Three major lines of evidence underscore the importance
of SOX10 for the function of Schwann cells. First, ablation
of Sox10 expression in mouse models causes: (i) a lack of
Schwann cells when performed during early development
[4]; (ii) lethality due to peripheral neuropathy when per-
formed in immature Schwann cells [5]; and (iii) demyelin-
ation of peripheral nerves when performed in terminally
differentiated Schwann cells [6]. Second, dominant-negative
SOX10 mutations cause an autosomal dominant disease
characterized by peripheral demyelinating neuropathy, cen-
tral dysmyelinating leukodystrophy, Waardenburg-Shah
syndrome, and Hirschsprung disease [7, 8]; the non-PNS
phenotypes reflect the role of SOX10 in other neural
crest derivatives (i.e., melanocytes and enteric neurons)
and in oligodendrocytes. Finally, mutations in SOX10
target genes including those encoding peripheral myelin
protein 22 (PMP22), myelin protein zero (MPZ), and
gap junction beta 1 (GJB1) cause demyelinating periph-
eral neuropathy [9–13].
The identification of additional SOX10 response ele-
ments and target loci will provide important information
on the process of myelination in the peripheral nerve as
well as novel target sequences to scrutinize for muta-
tions and modifiers of peripheral neuropathy. Indeed,
genome-wide analyses have been essential for character-
izing SOX10 biology in Schwann cells [14, 15]; however,
these efforts have primarily focused on identifying
positive regulators of myelination by examining tissues
or cells in a myelinating state. Thus, less-biased ap-
proaches are needed to complement the above studies
and to identify functions of SOX10 outside of the regu-
lation of promyelinating loci.
Here, we describe a stringent computational strategy
to rapidly predict SOX10 response elements in the
human genome. Combined with molecular functional
studies, this strategy revealed that SOX10 positively reg-
ulates the expression of SOX5, SOX6, NOTCH1,
HMGA2, HES1, MYCN, ID4, and ID2. Interestingly, each
of these genes has a known or predicted role in the
negative regulation of glial cell differentiation. As such,
we identified a putative novel role for SOX10 in
Schwann cells and present a model where SOX10 acti-
vates the expression of negative regulators of myelin-
ation to temper the pro-myelinating program during
non-myelinating stages of Schwann cell development.
Results
Genome-wide prediction of SOX10-responsive transcriptional
regulatory elements
SOX10 binds to a well-defined consensus sequence
(‘ACACA’ or ‘ACAAD’; where ‘D’ is a G, T, or A nucleo-
tide) as a monomer or as a dimer when two consensus se-
quences are oriented in a head-to-head fashion [14, 16].
To identify putative SOX10 binding sites in the human
genome, we wrote a Perl script to scan each human
chromosome and report all occurrences of the above
SOX10 consensus sequence. This revealed over 33 million
monomeric consensus sequences (Additional file 1) and
~549,000 dimeric consensus sequences with an interven-
ing sequence of five to 10 base pairs (Additional file 2).
Multiple-species conservation analysis is an effective
approach for predicting non-coding DNA sequences with
a role in transcriptional regulation [17]. Importantly, func-
tionally validated SOX10 binding sites have been identified
in non-coding genomic sequences that are conserved be-
tween human and chicken [18–20]. To prioritize the large
dataset of SOX10 consensus sequences, we aligned the
human, mouse, and chicken genomes and identified all
genomic sequences that are five base pairs or longer (the
length of the monomeric SOX10 consensus sequence)
and that are identical between these three species. This re-
vealed over two million conserved coding and non-coding
genomic segments (Additional file 3).
To develop a panel of prioritized SOX10 consensus se-
quences for functional studies, we used the rationale
that: (1) focusing on conserved dimeric SOX10 consen-
sus sequences will enrich for bona fide SOX10 binding
sites; (2) focusing on non-coding sequences will deprior-
itize sequences that are conserved due to the function of
the gene product; and (3) focusing on proximal pro-
moter and intronic sequences will provide a candidate
target gene for further studies. Thus, we compared the
above datasets to identify dimeric SOX10 consensus se-
quences that are conserved between human, mouse, and
chicken (including the intervening sequence), reside in
non-coding sequences, and map to an intron or 2.5 kb
upstream or downstream of a known (RefSeq) human
gene. This revealed 238 genomic sequences at 160 loci
for further study (Additional file 4). To determine the ef-
ficacy of our approach, we further prioritized the above
238 genomic segments by identifying the subset that
map to loci with a known or predicted role in myelin-
ation (see methods for details). This revealed 57 genomic
sequences at 32 loci with a conserved, dimeric SOX10
consensus sequence that resides within an intron or
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directly upstream of a myelin-related transcriptional unit;
we named these elements SOX10 Conserved Consensus
Sequences (SOX10-CCS; Additional file 5).
Seven conserved SOX10 consensus sequences display
regulatory activity in Schwann cells
Using our computational pipeline, we identified 57
regions that harbor conserved head-to-head SOX10
consensus sequences at loci with a known or predicted
role in myelination. To test if these sequences are active in
Schwann cells in vitro, a region surrounding each consen-
sus sequence (Additional file 5) was amplified from hu-
man genomic DNA and cloned upstream of a minimal
promoter directing the expression of a luciferase reporter
gene. The regulatory activity of each genomic segment
was tested in cultured rat Schwann (S16) cells [21, 22],
which express endogenous SOX10 [19]. The luciferase
expression directed by each genomic segment was deter-
mined in luciferase activity assays compared to a control
vector with no genomic insert (‘Empty’). Seven of the 57
genomic segments demonstrated a greater than 2.5-fold
increase in luciferase activity compared to the empty vec-
tor in S16 cells (Fig. 1): SOX10-CCS-01 (3.7-fold increase;
maps to PAX7), SOX10-CCS-13 (54-fold increase; maps
to SOX6), SOX10-CCS-18 (82-fold increase; maps to
SOX5), SOX10-CCS-19 (49-fold increase; maps to SOX5),
SOX10-CCS-39 (5.9-fold increase; maps to TCF7L2),
SOX10-CCS-43 (25-fold increase; maps to BCAS3), and
SOX10-CCS-51 (2.6-fold increase; maps to NFIB). These
data suggest that these seven genomic sequences (Table 1)
are potential SOX10 response elements.
The SOX10 consensus sequence is required for the
orientation-independent activity of three regulatory
elements at SOX5, SOX6, and NFIB
To determine if the regulatory activity of the seven gen-
omic segments is dependent on the orientation of the
DNA sequence, we retested the activity of each segment
in both the ‘forward’ and ‘reverse’ orientation relative to
a construct with no genomic insert (‘Empty’) within our
reporter gene construct in S16 cells. This revealed three
genomic segments that enact a greater than 2.5-fold in-
crease in luciferase activity in both orientations (Fig. 2a):
SOX10-CCS-13 (72-fold forward and 9-fold reverse),
SOX10-CCS-19 (70-fold forward and 33-fold reverse),
and SOX10-CCS-51 (4-fold forward and 9-fold reverse).
To assess the specificity of these results to Schwann
cells, we tested each of the seven genomic segments in
both orientations in cultured mouse motor neurons
(MN1 cells) [23], which do not express endogenous
SOX10 [19]. None of the genomic segments enact a
greater than 2.5-fold increase in luciferase activity in
both orientations in MN1 cells suggesting that our
data in S16 cells is Schwann-cell specific; however,
three had low levels of activity in only the forward
orientation in MN1 cells (Additional file 6: Figure S1):
SOX10-CCS-39 (5.5-fold), SOX10-CCS-43 (6.7-fold), and
SOX10-CCS-51 (4-fold).
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Fig. 1 Seven regions demonstrate regulatory activity in Schwann cells. Each of the 57 genomic segments containing prioritized SOX10 consensus
sequences was cloned upstream of a luciferase reporter gene and tested for enhancer activity in cultured Schwann (S16) cells. Luciferase data are
expressed relative to a control vector that does not harbor a genomic insert (‘Empty’). Regions that display a greater than 2.5-fold increase (red line)
in luciferase activity are indicated in red text and by an arrow. Error bars indicate standard deviations
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To test the necessity of the conserved SOX10 consen-
sus sequence for the observed activity associated with
the seven genomic segments described above, we deleted
the dimeric SOX10 site along with the intervening
sequence in each construct (ΔSOX10) and compared the
activity to the wild-type genomic segment using the
more active orientation. This revealed three genomic
segments that display at least a 50 % reduction in activ-
ity upon deleting the SOX10 consensus sequence
(Fig. 2b): SOX10-CCS-13, SOX10-CCS-19, and SOX10-
CCS-51. Combined, our data are consistent with these
three genomic segments—at the SOX6, SOX5, and NFIB
loci, respectively—representing Schwann cell enhancers
that harbor functional SOX10 binding sites.
SOX10 is required for the activity of the three regulatory
elements at SOX5, SOX6, and NFIB
To test if SOX10 induces the activity of SOX10-CCS-13,
SOX10-CCS-19, and SOX10-CCS-51, we co-transfected
each reporter gene construct with or without a construct
to express wild-type SOX10 in MN1 cells, which do not
express endogenous SOX10 [8, 19]. Subsequently, we
compared the activity of each construct in the presence
or absence of SOX10 expression. There was a ~1,000-
fold increase in the activity of SOX10-CCS-13 and a
~200-fold increase in the activities of SOX10-CCS-19
and SOX10-CCS-51 in the presence of SOX10 (Fig. 3a).
SOX8, SOX9, and SOX10 belong to the SOXE family of
transcription factors, which bind to nearly identical se-
quence motifs [24]. To test if SOX10 specifically regulates
SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51, we
co-transfected each reporter construct with or without a
construct to express SOX8 or SOX9 in MN1 cells [19, 25]
and compared the effect on regulatory activity with that
induced by SOX10. In the presence of SOX8 we observed
a ~140-fold, ~75-fold, and ~50 fold increase in the activity
of SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51,
respectively (Additional file 7: Figure S2). In the presence
of SOX9 we observed a ~350-fold, ~150-fold, and ~80-fold
increase in the activity of SOX10-CCS-13, SOX10-CCS-19,
and SOX10-CCS-51, respectively (Additional file 7:
Figure S2). Importantly, SOX8 and SOX9 did not in-
crease the luciferase activity of these regions to the same
level as SOX10 (Additional file 8: Figure S3), suggesting
that SOX10 has a higher affinity for the sequences within
SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51.
SOX10 is known to synergistically interact with other
transcription factors to enact gene expression [OCT6,
BRN2, and EGR2 in Schwann cells, OLIG2 and MYRF
in oligodendrocytes [26], and PAX3 and MITF in mela-
nocytes [27]]. Thus, we wanted to determine if the most
well-characterized co-factor in Schwann cells (EGR2)
works synergistically to activate these elements. EGR2, a
master regulator of Schwann cell myelination, is regu-
lated by SOX10, OCT6, and BRN2 [28]. SOX10 and
EGR2 synergistically regulate key myelin genes such as
PMP22 [10], MPZ [11], and GJB1 [9]. We co-transfected
SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51
reporter constructs with a construct to express EGR2
and SOX10 in MN1 cells and compared the effect on
regulatory activity with that induced by SOX10 alone
(Additional file 8: Figure S3). In the presence of EGR2
we observed a moderate increase in luciferase activity of
SOX10-CCS-13 (~2.2-fold), SOX10-CCS-19 (~12-fold) and
SOX10-CCS-51 (~10-fold) (Additional file 8: Figure S3).
However, in the presence of both EGR2 and SOX10 we did
not see an increase in activity above that induced by
SOX10 alone (even though an equivalent amount of
SOX10 expression vector was transfected in each experi-
ment). These data suggest that the three regions are
primarily regulated by SOX10 and that EGR2 and SOX10
do not act synergistically upon them.
To determine if SOX10 is necessary for the activity of
SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51 in
Schwann cells, S16 cells were transfected with each
SOX10-CCS luciferase reporter gene construct along
with a construct to express a dominant-negative mutant
form of SOX10 (E189X), which interferes with the
function of endogenous SOX10 [8]. Importantly, E189X
SOX10 has been shown to specifically reduce the activity
of genomic segments harboring SOX10 binding sites in
luciferase assays [29]. We observed a greater than 85 %
Table 1 Seven genomic segments with regulatory activity in Schwann cells
Element ID Locus UCSC coordinatesa SOX10 Consensus sequenceb
SOX10-CCS-01 PAX7 chr1:18,854,300-18,855,055 ACAAACTCATTAAACTTGT
SOX10-CCS-13 SOX6 chr11:16,334,301-16,335,278 ACAATCAAGCATTGT
SOX10-CCS-18 SOX5 chr12:24,058,988-24,059,872 ACAAAAATGTATTGT
SOX10-CCS-19 SOX5 chr12:24,059,397-24,060,164 ACACAGAACATTATTGT
SOX10-CCS-39 TCF7L2 chr10:114,894,980-114,895,808 ACAATCCCCAAGATTTTTGT
SOX10-CCS-43 BCAS3 chr17:56,683,905-56,684,657 ACACATTAATAACGTTTTGT
SOX10-CCS-51 NFIB chr9:14,299,332-14,299,796 ACAATCTGTTCTTTGTGT
aCoordinates refer to the March 2006 UCSC Genome Browser Human assembly (hg18)
bSOX10 consensus sequences are indicated in bold, underlined text
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reduction in the activity of all three genomic segments
upon co-transfection with E189X SOX10 (Fig. 3b).
Combined, our data indicate that SOX10 is required for
the in vitro enhancer activity of SOX10-CCS-13,
SOX10-CCS-19, and SOX10-CCS-51.
SOX10-CCS-13 is a previously unreported, alternative
Sox6 promoter
Examination of SOX10-CCS-13 on the UCSC Genome
Browser revealed that the SOX10 consensus sequence
within this genomic segment is also conserved between
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Gopinath et al. BMC Genomics  (2016) 17:887 Page 5 of 16
human and zebrafish (data not shown) further suggesting
an important role for this SOX10 response element in
jawed vertebrates. Therefore, to validate our computational
approach we pursued additional analyses of SOX10-CCS-
13, which resides at the SOX6 locus. Closer scrutiny of the
SOX6 locus on the UCSC Genome Browser [30] revealed
seven unique SOX6 mRNA isoforms in human, mouse, or
rat, distinguished by alternative, non-coding first exons.
Interestingly, SOX10-CCS-13 maps directly upstream of
the 3’-most alternative first exon, which we named SOX6
exon 1G (Fig. 4). We therefore hypothesized that SOX10-
CCS-13 acts as an alternative promoter at SOX6. To test
this, we performed 5’-rapid amplification of cDNA ends
(5’-RACE). Briefly, a cDNA library was generated using
RNA isolated from cultured rat Schwann (S16) cells and a
reverse primer in exon 5 of the rat Sox6 gene. Subse-
quently, nested PCR was performed using reverse primers
in exon 4 and then exon 3 of Sox6. The PCR products were
cloned, sequenced, and aligned to the rat Sox6 locus. These
analyses revealed the presence of five unique Sox6 tran-
scription start sites in cultured Schwann cells with 14 of
the 44 Sox6-specific sequences mapping directly down-
stream of SOX10-CCS-13 (Fig. 4). Analysis of RNA-seq
data generated in S16 cells (Antonellis and Law, in
preparation) also revealed reads that map to Sox6 exon
1G (Fig. 4), with split reads into downstream exons, but
no split reads into upstream exons (data not shown).
Additionally, we were able to amplify and sequence-
verify a full length Sox6 mRNA that originates at exon
1G in S16 cells (Fig. 4).
To assess the in vivo relevance of SOX10-CCS-13 we
analyzed recently published SOX10 ChIP-seq data per-
formed on nuclei isolated from rat spinal cord and sciatic
nerve [14, 15]. Furthermore, to establish that this genomic
segment resides in open chromatin we performed DNase-
seq analysis on nuclei isolated from cultured rat Schwann
(S16) cells (see below). The SOX10 ChIP-seq analyses re-
vealed that SOX10 binds to SOX10-CCS-13 in relevant
tissues in vivo and the DNase-seq experiment revealed
that this genomic segment resides in open chromatin in
cultured Schwann cells (Fig. 4, green box). Combined,
these data support our conclusion that SOX10-CCS-13 is
a SOX10 response element in Schwann cells. Interestingly,
these genome-wide functional studies revealed additional
SOX10 binding sites at Sox6 in vivo further supporting
the notion that Sox6 is a SOX10 target gene (e.g., brown
highlighted region in Fig. 4). Combined, our data indicate
that SOX10-CCS-13 represents an internal, alternative,
SOX10-responsive promoter at Sox6.
SOX10 is necessary and sufficient for the expression of
Sox6 transcripts harboring exon 1G
To determine if SOX10 is sufficient to direct the expres-
sion of Sox6 transcripts, we performed RT-PCR using
primers designed in Sox6 exon 1G and exon 2 in regions
conserved between rat and mouse. While these primers
amplify Sox6 transcripts containing exon 1G from a
0 
20 
40 
60 
80 
100 
120 
140 
1200 
0 
200 
400 
600 
800 
1000 
Lu
ci
fe
ra
se
 a
ct
iv
ity
 r
el
at
iv
e 
to
 u
nt
re
at
ed
Motor Neurons (MN1)
SOX10-CCS-13
WT SOX10 +-
SOX10-CCS-19
+-
SOX10-CCS-51
+-
Lu
ci
fe
ra
se
 a
ct
iv
ity
 r
el
at
iv
e 
to
 u
nt
re
at
ed
Schwann (S16) Cells 
E189X SOX10
SOX10-CCS-13
+- +-
SOX10-CCS-51
+-
SOX10-CCS-19
A
B
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E189X SOX10. Error bars indicate standard deviations in both panels
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cDNA library generated from S16 RNA, we were not
able to amplify these transcripts from a cDNA library
generated from cultured mouse motor neurons (MN1
cells), which do not express endogenous SOX10 (Fig. 5a).
However, when MN1 cells were transfected with a con-
struct to express wild-type SOX10, Sox6 transcripts
containing exon 1G were detected and verified by DNA
sequence analysis. Mock transfection or transfection
with a construct to express a non-functional mutant
version of SOX10 (E189X) [8] did not allow amplifica-
tion of Sox6 transcripts containing exon 1G (Fig. 5a).
Thus, SOX10 is sufficient to activate the expression of
Sox6 transcripts harboring exon 1G in MN1 cells.
To determine if SOX10 is necessary for the expression
of Sox6 transcripts containing exon 1G in Schwann cells,
we treated S16 cells with a previously validated siRNA
against Sox10 [15, 20] and tested for an effect on total
Sox6 mRNA levels and for an effect on the level of tran-
scripts containing exon 1G. This analysis revealed a
~70 % decrease in both total Sox6 expression and in the
expression of transcripts containing exon 1G (Fig. 5b),
consistent with SOX10 regulating the promoter activity
of SOX10-CCS-13 in Schwann cells. Combined, our data
indicate that SOX10 is both necessary and sufficient for
the expression of Sox6 mRNA isoform 7 (Fig. 4) in our
in vitro cell culture model systems.
SOX10 regulates the expression of genes that inhibit
myelination
Our stringent computational and functional analyses rap-
idly identified a previously unreported SOX10-responsive
promoter at the SOX6 locus. Importantly, this finding was
facilitated by the knowledge of a well-defined SOX10 con-
sensus sequence and reports that SOX10 binding sites can
be conserved among vertebrate species including human
and chicken [18–20]. To determine if our conservation
analysis combined with whole genome datasets can reveal
a set of high-confidence SOX10 response elements for
further study we: (1) utilized available SOX10 ChIP-seq
data generated from rat Schwann cell nuclei in vivo [14];
Fig. 4 SOX10-CCS-13 is an alternative promoter at the Sox6 locus. The ~579 kb rat Sox6 locus is shown on the UCSC Rat Genome Browser. SOX10-
CCS-13 is indicated in red along with the seven human, mouse, and rat SOX6 RefSeq mRNAs (blue). Sox6-specific 5’ RACE was performed on RNA from
S16 cells and the five distinct Sox6 sequences were mapped to the rat genome. Please note that SOX10-CCS-13 maps to both the 5’ end of
the seventh Sox6 mRNA and the fifth unique 5’ RACE-generated sequence. RNA-Seq data from S16 cells were mapped to Sox6 (the y-axis indicates
sequence read depth) as was a PCR-amplified, full-length mRNA that contains Sox6 exon 1G. Genome-wide regulatory marks were also
mapped to Sox6 with the Y-axes indicating normalized sequence read depths (both SOX10 ChIP-seq data sets) and F-Seq scores (DNase-seq).
The green highlighted region marks the general position of SOX10-CCS-13 across all data sets and the brown highlighted region marks another potential
SOX10 response element at Sox6
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(2) performed DNase-seq on cultured rat Schwann (S16)
cell nuclei; and (3) identified 67,482 non-coding SOX10
monomeric consensus sequences conserved between hu-
man, mouse, and chicken (data not shown), and converted
them to the rat genome [rn5; 61,133 (90.5 %) were
successfully converted]. Intersecting these three data sets
revealed 214 rat genomic segments that harbor conserved
SOX10 consensus sequences and that map to SOX10
ChIP-seq and DNase-seq peaks (Additional file 9; these
genomic segments were computationally extracted as
SOX10 ChIP-seq peaks). To determine if this approach
identified specific biological pathways, we extracted
the name of the rat RefSeq gene closest to each
region—the 214 genomic segments map to 191 known
genes (Additional file 9)—and performed a gene ontology
search using the overrepresentation test for biological
processes (geneontology.org). This analysis revealed 183
biological processes with a p-value less than 0.05 and 37
biological processes that showed a greater than five-fold
enrichment compared to the human genome. Ten of the
identified biological processes directly relate to myelinat-
ing glia, which all resided in the top 14 enriched terms
(Table 2). Therefore, this combined strategy provided a
highly confident set of 214 SOX10-response elements
at 191 loci for future functional studies aimed at better
understanding the biological process of myelination
(Additional file 9).
Interestingly, three of the 10 gene ontology biological
processes that relate to myelination specifically relate to
negative regulation of gliogenesis, which was due to the
presence of six genes: NOTCH1, HMGA2, HES1, MYCN,
ID4, and ID2 (Table 2). Computational analyses revealed
eight SOX10 consensus sequences within DNase-seq and
SOX10 ChIP-seq peaks at these six loci (Table 3). To
determine if NOTCH1, HMGA2, HES1, MYCN, ID4, and
ID2 harbor bona fide SOX10 response elements, we amp-
lified genomic regions surrounding the SOX10 consensus
sequences using rat genomic DNA and cloned each gen-
omic segment (in both the ‘forward’ and ‘reverse’ orienta-
tion) upstream of a minimal promoter directing luciferase
expression. The regulatory activity of each genomic seg-
ment was tested in S16 cells as described above. This
revealed five genomic segments (‘regions’ or ‘R’) that di-
rected reporter gene activity at least 2.5-fold higher than
the empty control vector in both orientations: Notch1-R1
(4.7-fold forward and 56-fold reverse), Hmga2-R2 (93.7-
fold forward and 87-fold reverse), Hes1-R1 (22-fold for-
ward and 7.6-fold reverse), Mycn-R1 (28-fold forward and
16-fold reverse) and Id2-R1 (8.9-fold forward and 4.1-fold
reverse) (Fig. 6a). Regions Notch1-R2 (7.6-fold) and Id4-R1
(8.6-fold) directed reporter gene activity at least 2.5-fold
higher than the empty control vector only in the forward
orientation (Fig. 6a). Hmga2-R1 was not active in either
orientation and was excluded from further analysis.
Thus, we identified seven genomic sequences at six
loci (NOTCH1, HMGA2, HES1, MYCN, ID4, and ID2)
that display regulatory activity in Schwann cells.
To determine if the identified SOX10 consensus se-
quences (Table 3) are important for the regulatory activ-
ity of the seven active regions described above (Fig. 6a)
we deleted the SOX10 consensus sequence from each
construct (termed ‘ΔSOX10’ in Fig. 6b) and compared
the activity to the wild-type construct using the more
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Fig. 5 SOX10 is necessary and sufficient for SOX6 expression. a RT-PCR
was performed to detect the expression of Sox6 transcripts harboring
exon 1G using cDNA isolated from S16 cells, MN1 cells, or MN1 cells
transfected with no expression construct (mock) or a construct to
express wild-type or dominant-negative (E189X) SOX10. Base pair
(bp) ladders are indicated on the left. RT-PCR for β-actin and samples
including no cDNA (‘Blank’) were employed as positive and negative
controls, respectively. Please note that while the same primers were
used for each reaction, the rat (S16) PCR product was 402 base pairs
and the mouse (MN1) PCR product was 349 bp; the rat genome
harbors a 53 base pair rat-specific insertion, which we confirmed
via DNA sequence analysis. b Rat Schwann (S16) cells were treated
with a control siRNA (left side) or a siRNA targeted against Sox10 (right
side). Quantitative RT-PCR was used to measure expression levels of
total Sox6 (green bars) or Sox6 exon 1G-containing (purple bars)
transcripts. Error bars indicate standard deviations
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active orientation. Notch1-R1, Notch1-R2, Hmga2-R2,
Hes1-R1, and Id2-R1 contain dimeric SOX10 consensus
sequences, which were deleted along with the interven-
ing sequence. Mycn-R1 contains a monomeric consensus
sequence (ΔSOX10-1) and a dimeric consensus sequence
(ΔSOX10-2), which were independently deleted. Id4-R1
contains a dimeric consensus sequence with a 20 base-
pair intervening sequence. Since this intervening sequence
is longer than those previously observed for validated di-
meric SOX10 binding sites [16, 18–20, 29, 31] we studied
each monomer independently. Specifically, we deleted the
dimeric consensus sequence along with intervening
sequence (ΔSOX10-1), the first monomer only (ΔSOX10-
2), and the second monomer only (ΔSOX10-3). Deleting
the SOX10 consensus sequences in regions Notch1-R1,
Hmga2-R2, Mycn-R1 (ΔSOX10-2), Id4-R1 (ΔSOX10-1
and ΔSOX10-3), and Id2-R1 reduced luciferase activity in
S16 cells by at least 50 % (Fig. 6b), indicating that the
SOX10 consensus sequences in these five regions are im-
portant for their regulatory activity. In contrast, deleting
the SOX10 consensus sequences in Notch1-R2 and Hes1-
R1 did not reduce the enhancer activity associated with
these genomic segments (Fig. 6b).
We have shown that SOX10 directly regulates SOX6
in Schwann cells (see above). To determine if SOX10
positively regulates the expression of Notch1, Hmga2,
Hes1, Mycn, Id4, Id2, and Sox5 in cultured rat Schwann
(S16) cells we again utilized the Sox10 siRNA that has
been shown to efficiently down-regulate Sox10 expression
[15, 20]. After isolation of mRNA at 24 h post-
transfection, qRT-PCR shows that Sox10 depletion in S16
cells results in the reduced expression of all of the above
genes except for Hmga2 (Fig. 6c). Similar findings—in-
cluding the absence of reduced Hmga2 expression—were
observed upon repressing SOX10 function in vivo using
primary Schwann cells; however, this system is prone
to variability due to heterogeneous cell populations
(Additional file 10: Figure S4).
To directly test if NOTCH1, HMGA2, HES1, MYCN,
ID4, ID2, SOX5, and SOX6 are developmentally regu-
lated during myelination in vivo we examined mRNA
levels at three timepoints in rat sciatic nerve (n = 3 at
Table 2 Gene ontology annotations of loci harboring conserved SOX10 binding sites
GO biological process complete Human Our list Expected P-value Loci
Negative regulation of oligodendrocyte differentiation 12 4 0.1 2.74E-02 HES1, ID2, NOTCH1, ID4
Negative regulation of glial cell differentiation 25 6 0.21 6.34E-04 HES1, ID2, NOTCH1, HMGA2, MYCN, ID4
Regulation of astrocyte differentiation 25 6 0.21 6.34E-04 HES1, ID2, NOTCH1, HMGA2, MYCN, ID4
Regulation of oligodendrocyte differentiation 28 5 0.23 3.29E-02 HES1, TCF7L2, ID2, NOTCH1, ID4
Negative regulation of gliogenesis 34 6 0.28 3.77E-03 HES1, ID2, NOTCH1, HMGA2, MYCN, ID4
Oligodendrocyte differentiation 60 10 0.5 9.43E-07 SOX6, NTRK2, PTPRZ1, SOX8, SOX10, TCF7L2, ID2,
NOTCH1, SOX5, ID4
Regulation of gliogenesis 74 10 0.61 6.96E-06 PTPRZ1, SOX8, HES1, SOX10, TCF7L2, ID2, NOTCH1,
HMGA2, MYCN, ID4
Regulation of glial cell differentiation 54 7 0.45 3.23E-03 HES1, TCF7L2, ID2, NOTCH1, HMGA2, MYCN, ID4
Glial cell differentiation 135 13 1.12 1.22E-06 SOX6, PTPRZ1, NTRK2, SOX8, HES1, SOX10, TCF7L2,
ID2, NOTCH1, PPAP2B, SOX5, ID4, PARD3
Gliogenesis 168 13 1.39 1.66E-05 SOX6, PTPRZ1, NTRK2, SOX8, HES1, SOX10, TCF7L2,
ID2, NOTCH1, PPAP2B, SOX5, ID4, PARD3
Table 3 Eight genomic segments within loci that inhibit glial cell differentiation
Element ID UCSC Coordinatesa SOX10 Consensus Sequenceb
Notch1-R1 chr3:9,307,836-9,308,296 ACAATGGGGCCTCTGT
Notch1-R2 chr3:9,308,175-9,309,096 ACAATCGGCTTTGT
Hmga2-R1 chr7:65,390,088-65,391,287 CTTAGACACAGCACTT
Hmga2-R2 chr7:65,427,912-65,428,606 ACACAGGCCCCTCTTTGT
Hes1-R1 chr11:77,415,315-77,415,779 TGTGTGAGCGCCATGTGT
Mycn-R1 chr6:51,229,947-51,230,533 ACAATGGCCTCTTTCTACAGACAAT
Id4-R1 chr17:18,701,460-18,702,118 ACAAAAACAGCAGTAAATGGAGGCCTTTGT
Id2-R1 chr6:53,090,794-53,091,254 ACAAGAAACACATTGT
aCoordinates refer to the March 2012 UCSC Genome Browser Rat assembly (rn5)
bSOX10 consensus sequences are indicated in bold, underlined text
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each timepoint). P1 corresponds to the onset of myelin-
ation, P15 is a peak timepoint of myelination in the
PNS, and adult sciatic nerve is a timepoint where active
myelination has subsided. Interestingly, the expression
of all seven genes tested (Notch1, Hmga2, Hes1, Mycn,
Id4, Id2, Sox5, and Sox6) are highest at P1 and then
repressed at P15 and adult, consistent with a role in
repressing precocious myelination (Fig. 6d).
Discussion
Previous efforts have identified SOX10 binding sites and
target genes in Schwann cells [14, 15]. These efforts, and
others [32], have utilized a variety of experimental meth-
odologies to identify putative SOX10 regulatory ele-
ments across diverse SOX10-positive tissues. While each
approach uncovered novel SOX10 response elements,
no single method has been successful in the identifica-
tion of all SOX10 response elements. While the strat-
egies presented here also are unable to fully capture all
SOX10 binding sites, the combination of multiple
datasets and methodologies generally yields a stronger
predictive power for identifying regulatory regions com-
pared to any one individual method [33]. Indeed, when
we combined our DNase-seq data with previously gener-
ated SOX10 ChIP-seq data [14], we were able to quickly
prioritize and validate novel SOX10 response elements
near genes with a known role in myelination. While
previous efforts to identify SOX10 response elements
focused on the required function of SOX10 in cultured
cells or tissues at specific developmental stages, our
computational approach utilizes sequence conservation
to identify putative SOX10 regulatory regions through-
out the genome in a tissue-independent manner. The
combination of our less-biased (albeit less biologically
relevant) computational approach with DNase-seq and
ChIP-seq is likely the reason that we were able to iden-
tify specific repressors of myelination as putative SOX10
target genes (e.g., these would not have been identified
in myelinating Schwann cells). As such, we feel that the
datasets generated here will be useful to investigators
Fig. 6 SOX10 regulates the expression of genes that inhibit glial cell differentiation. a Eight genomic segments at the rat Notch1, Hmga2, Hes1,
Mycn, Id4, and Id2 loci were cloned upstream of a luciferase reporter gene in both the forward and reverse orientations and tested for luciferase
activity in rat Schwann (S16) cells. Luciferase data are expressed relative to a control vector with no genomic insert (‘Empty’). Error bars represent
standard deviations. b The conserved SOX10 consensus sequence(s) were deleted in each of the seven regions that were active in a (see text for
details). Luciferase reporter gene constructs containing the wild-type sequence (WT) or the sequence lacking the SOX10 consensus sequence(s)
(ΔSOX10) were transfected into S16 cells and luciferase assays performed. Luciferase activities are expressed relative to the wild-type expression
constructs and error bars represent standard deviations. c Rat Schwann (S16) cells were treated with a control siRNA or a siRNA targeted against
Sox10. Quantitative RT-PCR was used to measure expression levels of each indicated gene. Asterisks indicate a p-value smaller than 0.001 and error
bars indicate standard deviations. d RNA was purified from three independent rat sciatic nerves at the P1, P15, and adult timepoints. Quantitative
RT-PCR was used to measure expression levels of each indicated gene with values expressed relative to expression levels at P1. Asterisks indicate
a p-value smaller than 0.005 and error bars indicate standard deviations
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studying comparative genomics, SOX protein function,
and Schwann cell biology. First, the conserved sequences
we identified could be used to similarly prioritize consen-
sus sequences for other transcription factors important for
vertebrate development. Second, the SOX10 consensus se-
quences we identified could be used to prioritize putative
binding sites in other SOX10-positive cells including
oligodendrocytes, melanocytes, and developing enteric
nervous system neurons [34]. Finally, our DNase-seq
data from rat Schwann (S16) cells will be useful for
anyone studying transcriptional regulatory elements,
highly expressed genes, or any other nuclear structure
characterized by open chromatin in myelinating Schwann
cells; S16 cells express many myelin-related genes (e.g.,
PMP22, MPZ, MBP, and MAG) and transcription factors
(e.g., SOX10 and EGR2) and are biochemically similar to
myelinating Schwann cells [35].
The analyses performed here may also provide insight
into the nucleotide requirements for a SOX10 response
element. We functionally evaluated a total of 62 con-
served, genomic segments that harbor a predicted di-
meric SOX10 binding site. Interestingly, simply cloning
a highly conserved dimeric SOX10 consensus sequence
upstream of a minimal promoter was not enough to en-
act regulatory activity in cultured Schwann cells as evi-
denced by the 50 genomic segments with no (or very
low) regulatory activity in Fig. 1. While there are many
possible explanations for this finding, one is that there
are nucleotide-specific requirements for the intervening
sequences (i.e., the nucleotides between the head-to-
head monomeric sites). To assess this, we compared the
length and GC content of all 62 dimeric sites to those
dimeric sites that were both active and required for the
observed regulatory activity (n = 7). While there was no
significant difference in the average intervening se-
quence length between the two groups, the seven active
sites all had intervening sequence lengths between five
and eight nucleotides consistent with previous reports
that six basepairs provides the ideal spacing between
monomers [16]. Interestingly, there was a marked differ-
ence in the GC content when comparing the total popu-
lation of intervening sequences (GC content = 35 %) to
the intervening sequences in the active dimeric sites
(GC content = 61 %). These data are consistent with
the high GC content of the intervening sequences
within previously validated dimeric SOX10 binding
sites [13, 18–20, 29] and with a ‘G’ nucleotide being
the most commonly observed nucleotide after the
core motif [14]. Thus, future predictions of dimeric
SOX10 binding sites should allow for high GC con-
tent and five to eight basepairs between the head-to-
head consensus sequences.
Our efforts predicted eight putative SOX10 target loci
with a known role in repressing glial cell differentiation:
NOTCH1, HMGA2, HES1, MYCN, ID2, ID4, SOX5, and
SOX6. These findings were unexpected due to the
known role of SOX10 in regulating the expression of
genes that encode myelin proteins (e.g., MBP, MPZ, and
PMP22) [10, 12, 13, 31, 36, 37]. We showed that all eight
loci are developmentally regulated during myelination in
vivo in a manner consistent with a role in inhibiting glial
cell differentiation. We were also able to functionally
validate a SOX10 binding site at seven of the eight loci.
We identified a SOX10 ChIP-seq peak at HES1 and lu-
ciferase assays demonstrated that this genomic segment
has strong enhancer activity (Fig. 6a). However, deletion
of the predicted SOX10 binding sites in Hes1-R1
(Table 3) did not reduce luciferase activity. Further mu-
tagenesis of this genomic segment will be required to
identify sequences necessary for the observed activity,
which may reveal a degenerate SOX10 consensus se-
quence. When we depleted SOX10 activity in Schwann
cells in vitro and in vivo seven of the eight loci were
down-regulated; while HMGA2 harbors a validated
SOX10 response element (Fig. 6b), depletion of SOX10
activity did not reduce Hmga2 expression. Further analysis
will be required to determine if the SOX10 response elem-
ent at Hmga2 regulates an adjacent locus or if depletion of
SOX10 at specific developmental timepoints results in re-
duced Hmga2 expression. Consistent with our findings,
previous global analyses of SOX10 function revealed that
two of the above eight loci are downstream of SOX10: Id2
and Notch1 [14]; our analysis now localizes at least some
of the SOX10-dependent enhancers responsible for the
regulation of these two loci.
SOX5 and SOX6 are members of the SOXD family of
transcription factors and act as negative regulators of
myelination in the central nervous system [38]; these
proteins, which do not have transactivation or transre-
pression domains [39], inhibit the expression of SOX10
target genes (e.g., MBP) in oligodendrocytes by competing
with SOX10 for DNA binding at sites within cis-acting
regulatory elements. To allow oligodendrocyte differenti-
ation and myelin production, SOX6 mRNA is targeted for
degradation by two microRNAs (miR) in these cells: miR-
219 and miR-338 [40]. It was recently reported that
SOX13 (the third and final member of the SOXD sub-
group) also has an antagonistic effect on the ability of
SOX10 to activate the expression of myelin genes in the
central nervous system [41]. Indeed, SOX13 is among the
group of 191 loci at which we identified a highly confident
SOX10 binding site: a single, conserved genomic segment
within SOX10 ChIP-seq and DNase-seq peaks ~62 kb
upstream of Sox13 (rn5 coordinates chr13:55425486–
55425636) was identified (Additional file 9). Interestingly,
a relationship between SOXD and SOXE (SOX8, SOX9,
and SOX10) transcription factors has been proposed
since ablation of SOX8 or SOX9 (but not SOX10)
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reduces Sox6, but not Sox5, expression in the develop-
ing spinal cord [38].
In addition to genes encoding SOXD proteins, our
studies predict that NOTCH1, HES1, MYCN, ID2, and
ID4 are SOX10 target genes. NOTCH1 is a transmem-
brane receptor that regulates Schwann cell proliferation
and inhibits Schwann cell differentiation in perinatal
nerves, and facilitates dedifferentiation of Schwann cells
after nerve injury [42]. HES1 is an effector of NOTCH
signaling, acts as a transcriptional repressor [43, 44], and
is highly expressed during early stages of Schwann cell
development [42]. In cultured mouse oligodendrocytes,
HES1 maintains cells in an immature state and overex-
pression of HES1 results in reduced expression of myelin
related genes (Mbp and Plp) [45]. MYCN is a proto-
oncogene and is known to inhibit astrocyte differenti-
ation from neural precursor cells [46]; however, the role
of MYCN during Schwann cell myelination has not been
studied. Inhibitors of differentiation 2 and 4 (ID2 and
ID4) are known to inhibit oligodendrocyte differenti-
ation and the lack of both proteins results in premature
oligodendrocyte differentiation [47–49]. Furthermore,
Id2 and Id4 expression declines in Schwann cell devel-
opment and ID2 limits induction of myelin protein zero
expression in primary Schwann cells [50, 51]. Consistent
with our findings, RNA-seq of oligodendrocytes isolated
at various stages of mouse brain development [52]
show that Sox5, Sox6, Notch1, Hes1, Mycn, Id2, and
Id4 are developmentally regulated in the central ner-
vous system—Hmga2 does not appear to be expressed
in the cells assessed in that study. Therefore, these
genes likely play a role in preventing premature glial
cell differentiation in both the central and peripheral
nervous systems.
Combined with previous findings, our data predict a
model (Fig. 7) where SOX10 activates the expression of
genes that inhibit Schwann cell differentiation, possibly
during early stages of Schwann cell development, thus
preventing the precocious expression of myelin proteins.
Subsequently, EGR2, NAB, and microRNAs are known
to inhibit the expression of the negative regulators of
myelination (e.g., SOXD proteins), which would allow
the expression of myelin proteins. In addition to the data
presented in this study, previous reports support specific
aspects of this model. For example, EGR2 likely re-
presses the expression of many of the eight loci reported
here. EGR2 and NAB repress ID2 and ID4 before mye-
lination via NAB binding to CHD4 [51] [conditional
ablation of CHD4 in Schwann cells causes increased
expression of immature Schwann cell genes including
ID2 and delayed myelination, radial sorting defects,
hypomyelination, and the persistence of promyelinating
Schwann cells in conditional knockout mice [53]]. Fur-
thermore, a comparison of SOX10 and EGR2 binding
with expression profiles in Schwann cells treated with
siRNA for SOX10 and EGR2-deficent peripheral nerves
[14] revealed that NOTCH1 and ID2 are SOX10-activated
and EGR2-repressed, and ID2, HMGA2, SOX5, and ID4
remain high in peripheral nerves from Egr2- or Nab-
deficient mice [51, 54]. Finally, SOX10 directly regulates
the expression of EGR2 [28] and miR-338 [20]. In sum,
our findings suggest that SOX10 has a role in maintaining
a premyelinating state during non-myelinating stages of
Schwann cell development.
Conclusions
In this study, we developed a computational and func-
tional pipeline to expand the panel of known SOX10
response elements and target loci. These efforts predict
a novel function for SOX10 in repressing myelination in
early stages of Schwann cell (and possibly neural crest)
development. Furthermore, we provide useful datasets
for the scientific community and expand the mutational
screening space for disease-causing mutations—or modi-
fiers of disease—in patients with peripheral neuropathy
and other SOX10-related phenotypes.
Methods
Computational identification and prioritization of SOX10
consensus sequences
To identify all SOX10 consensus sequences in the human
genome we downloaded individual text files for each
human chromosome (hg18) from the UCSC Human Gen-
ome Browser [30] and wrote a Perl script (available upon
request) that examines each file for the consensus se-
quences (using a regular expression analysis) ‘ACACA’ or
Anti-myelination
No Myelination
SOX10 
Myelin Genes
(e.g., MBP and MPZ)
Negative Regulators
of Myelination
Pro-myelination
Myelination
SOX10 
Myelin Genes
(e.g., MBP and MPZ)
Negative Regulators
of Myelination
miRs 
EGR2
Fig. 7 A model for the role of SOX10 in maintaining a pre-
myelinating state. Previous to myelination (anti-myelination; left side),
SOX10 activates the expression of negative regulators of myelination,
which inhibit the expression of myelin genes such as MBP and MPZ.
During activation of the myelination program (pro-myelination; right
side), EGR2 and micro RNAs (miRs) inhibit the expression of negative
regulators of myelination, which allows SOX10 (and EGR2) to positively
regulate the expression of myelin genes
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‘ACAAD’; where ‘D’ is a G, T, or A nucleotide. To identify
two SOX10 consensus sequence monomers that are ori-
ented in a head-to-head manner (and that may represent
a dimeric SOX10 binding site) we wrote a second Perl
script that examines the human chromosome text files
and reports each ‘ACACA’ or ‘ACAAD’ consensus se-
quence that is five to 10 base pairs 5’ to the reverse com-
plement of this consensus sequence: ‘TGTGT’ or
‘HTTGT’, where ‘H’ represents an A, C, or T nucleotide.
To identify genomic sequences that are identical be-
tween human, mouse, and chicken we downloaded the
vertebrate (44 species) multiz alignment (maf) files from
the UCSC Human Genome Browser (hg18) and ex-
tracted the alignments for human, mouse, and chicken.
Next, we utilized the program ExactPlus [55] to identify
all human sequences that are at least 5 base pairs long
and identical between all three species. All subsequent
computational analyses that assess for overlap between
these and other datasets were performed using the
UCSC Table Browser [56] and the ‘intersection’ tool.
For these analyses we employed UCSC Genome cus-
tom tracks containing each: (1) human RefSeq (hg18)
protein-coding sequence to exclude coding sequences;
(2) human RefSeq entry (hg18) plus 2.5 kb upstream
and 2.5 kb downstream of the transcriptional unit to
identify regions that map to known genes; (3) SOX10
ChIP-seq peak in the rat genome (rn5) using HOMER
analysis [57] (Additional file 11) of previously de-
scribed P15 sciatic nerve data sets; and (4) DNase-seq
peak in the rat genome (rn5) that has an F-Seq [58]
score of at least 0.08 (see below).
To identify the 57 loci with a known or predicted role
in peripheral nerve myelination we performed the fol-
lowing PubMed searches in September 2014: (1) each
gene name plus ‘Schwann’; and (2) each gene name plus
‘Myelin’. We also searched for each gene name plus
‘Schwannoma’ in the GEO Profiles database at NCBI to
determine if gene expression is depleted upon treatment
with SOX10 siRNA [32].
Luciferase reporter gene expression constructs
Primers containing attB1 and attB2 Gateway cloning
(Invitrogen) sequences were designed for each region
identified by our computational pipeline (human gene-
specific primer sequences are provided in Additional file
5; rat gene-specific primer sequences are available upon
request). Regions were PCR-amplified using human or rat
genomic DNA and subsequently cloned into pDONR221
using BP clonase (Invitrogen) according to the manufac-
turer’s instructions. The pDONR221 constructs were se-
quence verified and cloned upstream of an E1B minimal
promoter [55] directing luciferase expression in the for-
ward (pE1B Forward) or reverse (pE1B Reverse) orienta-
tion using LR clonase (Invitrogen) according to the
manufacturer’s instructions. Mutagenic primers to delete
SOX10 consensus sequences (available upon request)
were designed and site directed mutagenesis performed
using the QuikChange II Mutagenesis Kit (Agilent Tech-
nologies) according to the manufacturer’s instructions.
The resulting mutant constructs were sequence verified to
ensure that the SOX10 consensus site was deleted and
that no other mutations were generated. Subsequently,
the constructs were recombined into the pE1B luciferase
vector as described above.
Cell culture and luciferase assays
Cultured rat Schwann cells (S16) [21, 22] were obtained
ten years ago from Richard Quarles (NIH/NINDS) and
mouse motor neuron derived cells (MN1) [23] were ob-
tained 12 years ago from Kurt Fischbeck (NIH/NINDS).
Both cell types were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10 % fetal bovine
serum (Gibco) and 2 mM L-glutamine (Gibco). For
luciferase assays, 1x104 cells were plated in each well of
a 96-well culture plate (Corning Life Sciences) and incu-
bated overnight at 37 °C in 5 % CO2. Cells were trans-
fected using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions. Each well was trans-
fected with 200 ng of the pE1B construct [55] and 2 ng
of pCMV-Renilla (to correct for experimental variation
caused due to cell viability and transfection efficiency) in
50 uL of Opti-MEM (Gibco) and 0.25 uL Lipofectamine
2000. Cells were incubated at 37 °C for 4 h and then
grown in standard growth media for 48 h. For overex-
pression studies, 100 ng of a construct to express wild-
type or E189X SOX10 [8], wild-type SOX8, SOX9, or
EGR2 was included in the transfection reaction. 48 h
after transfection the cells were lysed in 20 uL of 1X
passive lysis buffer (Promega) for 1 h. 10 uL of the lysate
was transferred to a 96-well assay plate (Corning Life
Sciences) and a Dual Luciferase Assay (Promega) was
performed to determine the activities of luciferase and
renilla. Luciferase activity was normalized to renilla ac-
tivity and the fold increase in luciferase activity was cal-
culated relative to the empty control vector, which does
not contain a genomic insert. For each genomic seg-
ment, three independently isolated reporter gene con-
structs were studied in eight technical replicates for a
total of 24 reactions per segment. Statistical calculations
comparing the regulatory activity of different alleles were
performed using the Mann–Whitney-Wilcoxon test.
Standard and quantitative RT-PCR
Total RNA was isolated from S16 and MN1 cells. 1x105
cells were plated in a 6-well plate and incubated over-
night at 37 °C in 5 % CO2. Each well was transfected
using 4 ug of wild-type or E189X SOX10 [8] in 1 mL of
Opti-MEM and 10 uL of Lipofectamine 2000. Mock
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transfections were performed in the absence of DNA.
Cells were incubated at 37 °C for 4 h and then grown in
standard media. After 72 h, total RNA was isolated from
the transfected cells using the RNeasy kit (Qiagen). Sub-
sequently, cDNA was synthesized using 1 ug of total
RNA and the High Capacity cDNA Reverse Transcrip-
tion Kit (Life Technologies) according to manufacturer’s
instructions. RT-PCR was performed on isolated cDNA
using gene specific primers (sequences available upon
request). A PCR for β-actin served as a positive control.
All PCR products were subjected to DNA sequencing to
confirm specificity. RNA was purified from three inde-
pendent rat sciatic nerves at the P1, P15, and adult time-
points using the Qiagen RNeasy Lipid kit, and quantitative
RT-PCR was performed as described [20].
5’ Rapid amplification of cDNA ends
First strand cDNA libraries were synthesized using total
RNA isolated from S16 cells and a primer designed
within exon 5 of Sox6. The cDNA was TdT-tailed using
the 5’RACE System (Invitrogen). Subsequently, two
nested PCRs were performed: one using a reverse primer
designed within exon 4 of Sox6 and a second using a
reverse primer designed within exon 3 of Sox6 (primer
sequences available upon request). The nested PCR
products were separated on a 1 % agarose gel, excised,
and purified using the QIAquick gel extraction kit
(Qiagen). Gel purified PCR products were TA cloned
(Invitrogen) according to manufacturers instructions
and 48 clones were subjected to Sanger sequencing:
44 of the resulting sequences correctly mapped to the
rat Sox6 locus.
siRNA-mediated depletion of SOX10
Control siRNA (siControl 1, Ambion catalog number
AM4611) or Sox10 siRNA (siSox10 1, Life Technologies
catalog number s131239) were transfected into S16 cells as
described using the Amaxa Nucleofection system following
the manufacturer’s instructions. At 48 h post-transfection,
RNA was isolated using Tri-Reagent (Ambion) and ana-
lyzed by quantitative RT-PCR as described [20].
DNase hypersensitivity site identification
DNase-seq was performed with three biological repli-
cates of rat Schwann (S16) cells at passage numbers five,
eight, and 14. Each replicate contained ~20 million cells
frozen into 1 ml of freezing media. Cells were thawed
and DNase-seq libraries generated as previously de-
scribed [59] with the exception of adding a 5’ phosphate
to linker 1 to increase the ligation efficiency. DNase-seq
libraries from three replicates were pooled into one lane
of an Illumina Hi-Seq 2000. Raw reads were aligned
to the rat (rn5) genome using Bowtie [60] and unique
mapping with up to two mismatches allowed in an
alignment. For the three samples, 69.2 % (36,295,401),
70.8 % (43,564,606), and 67.9 % (39,579,719) of the
reads mapped to rn5. Peaks were called using F-Seq
and the default settings [58]. For the three samples:
502,787 (sample 1), 438,254 (sample 2), and 412,267
(sample 3) peaks were identified. 149,342 were shared
among all three samples (Additional file 12). We next
used sample 2 as a representative experiment and ex-
tracted all DNase-seq peaks with an F-Seq score [52]
of at least 0.08. This revealed a set of 31,845 peaks
(7.3 %; Additional file 13) that were used to prioritize
SOX10 response elements (see section ‘Computational
identification and prioritization of SOX10 consensus
sequences’ above). Data from the three samples have
been submitted to GEO (GSM2166058, GSM2166059
and GSM2166060).
Additional files
Additional file 1: Monomeric SOX10 consensus sequences in the
human genome provided as a UCSC Human Genome Browser (hg18)
custom track. The fourth column (‘name’) shows the predicted SOX10
binding site sequence. (ZIP 222208 kb)
Additional file 2: Dimeric SOX10 consensus sequences with an
intervening sequence of five to 10 base pairs in the human genome
provided as a UCSC Human Genome Browser (hg18) custom track.
The fourth column (‘name’) shows the predicted SOX10 binding site
sequence. (TXT 22732 kb)
Additional file 3: Genomic segments at least five base pairs long and
conserved between human, mouse, and chicken provided as a UCSC Human
Genome Browser (hg18) custom track. The fourth column (‘name’) shows the
position and length of the conserved segment. (TXT 87756 kb)
Additional file 4: Genomic coordinates (hg18; UCSC Human Genome
Browser) of 238 SOX10 consensus sequences that are conserved between
human, mouse, and chicken and that map to non-coding sequences near
a RefSeq gene. Columns are labeled in the file. (XLSX 29 kb)
Additional file 5: Genomic coordinates (hg18; UCSC Human Genome
Browser) and primer sequences for 57 genomic segments studied in
luciferase assays presented in Fig. 1. Columns are labeled in the file.
(XLSX 44 kb)
Additional file 6: Figure S1. Three genomic regions display
orientation-specific regulatory activity in motor neurons. The seven active
regions from Fig. 1 were tested in forward (grey bars) and reverse (white
bars) orientation in mouse motor neuron (MN1) cells. Luciferase data are
expressed relative to a control vector without a genomic segment
(‘Empty’). The scale of the y-axis is the same as in Fig. 2 to allow
comparisons. Error bars indicate standard deviations. (PDF 97 kb)
Additional file 7: Figure S2. SOX8 and SOX9 also increase the regulatory
activity of SOX10-CCS-13, SOX10-CCS-19, and SOX10-CCS-51. Luciferase
reporter gene constructs harboring SOX10-CCS-13, SOX10-CCS-19, or
SOX10-CCS-51 were transfected into mouse motor neurons (MN1) with
constructs to express SOX8 or SOX9. The luciferase activity associated with
each construct in the presence of SOX8 or SOX9 is expressed relative to that
of the same construct in the absence of these transcription factors. Error bars
indicate standard deviations. Please note that the SOX10 data are identical to
those in Fig. 3a and are included to facilitate a comparison. (PDF 330 kb)
Additional file 8: Figure S3. EGR2 does not act synergistically with
SOX10 to activate SOX10-CCS-13, SOX10-CCS-19, or SOX10-CCS-51 in
vitro. Luciferase reporter gene constructs harboring SOX10-CCS-13,
SOX10-CCS-19, or SOX10-CCS-51 were transfected into mouse motor
neurons (MN1) with constructs to express EGR2 and/or SOX10. The
luciferase activity associated with each construct in the presence of the
Gopinath et al. BMC Genomics  (2016) 17:887 Page 14 of 16
transcription factor(s) is expressed relative to that of the untreated
reporter construct. Error bars indicate standard deviations. Please note
that the SOX10 data are identical to those in Fig. 3a and are included to
facilitate a comparison. (PDF 328 kb)
Additional file 9: Genomic coordinates and custom tracks (rn5; UCSC
Rat Genome Browser) for SOX10 ChIP-seq peaks that map to both a
DNase hypersensitivity site and at least one SOX10 monomeric consensus
sequence that is conserved between human, mouse, and chicken. Columns
are labeled in the file. (XLSX 23 kb)
Additional file 10: Figure S4. SOX10 regulates genes that inhibit glial
cell differentiation in vivo. Primary Schwann cells were extracted and
grown from three independent rat adult sciatic nerves. Cells were treated
with a control siRNA or an siRNA targeted against Sox10 as in Fig. 7c.
Quantitative RT-PCR was used to measure expression levels of each
indicated gene. The effect on expression of each gene (indicated across
the bottom) is expressed relative to the control siRNA and error bars
indicate standard deviations. Please note that, consistent with the in vitro
data, Hmga2 did not show a decrease in expression levels in vivo (data
not shown). (PDF 334 kb)
Additional file 11: SOX10 ChIP-seq peaks in the rat genome using
HOMER analysis. The data are provided as a UCSC Rat Genome Browser
(rn5) custom track. (TXT 1526 kb)
Additional file 12: DNase-seq peaks identified in S16 cells that are
common to all three experimental replicates. The data are provided
as a UCSC Rat Genome Browser (rn5) custom track and the fourth column
(‘name’) shows the F-Seq score for the peak. (TXT 5171 kb)
Additional file 13: DNase-seq peaks identified in S16 cells from
experimental sample 2 that have an F-Seq score of at least 0.08. The data are
provided as a UCSC Rat Genome Browser (rn5) custom track and the fourth
column (‘name’) shows the F-Seq score for the peak. (TXT 1075 kb)
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